Bacteriuria (Asymptomatic) in Pregnancy Clinical Trial
This is a prospective randomized controlled day comparing the efficacy of three-day antimicrobial treatment of asymptomatic bacteriuria (ASB) in pregnancy to the standard seven-day treatment. Half the patients will receive 3-day treatment and the other half will receive 7 days of antibiotics.
The current standard of practice is to treat pregnant patients with ASB with a 7-day course
of oral antimicrobial agents. If bacteriuria persists women are retreated with the same of
different agent for a second course of 7 to 14 days and they may be subsequently placed on
prophylaxis.
In nonpregnant women, an uncomplicated lower urinary tract infection may be treated with a
short course regimen from 1 to 3 days. This approach has similar rates of persistent
bacteriuria or symptoms following treatment when compared to women treated with a more
conventional approach. If the infection recurs or persists, the patient may then be treated
with the more traditional 7 to 14 day course. The advantages of single-dose regimens are cost
and patient compliance, but a major disadvantage is the failure to eradicate uropathogens
from the vaginal reservoir, which results in more frequent early recurrences.
The three-day regimen is advocated to maintain the advantages of lower costs and patient
compliance but improving cure rates. Multiple studies have shown the advantage of even a
short course of antibiotics as opposed to no treatment.
;